All 72 resections for colorectal liver secondaries during the period 1971-1984 were analysed retrospectively. Liver tumours were single in 35 (49 per cent), unilateral in 55 (76 per cent) and associated with extrahepatic disease in 12 (18 per cent) patients. Operative mortality was 5.6 per cent. With respect to the disease in the liver, the presence or absence of four or more metastases was the predominant prognostic determinant with a 5 year survival rate of 20 per cent in patients with less than four liver tumours, and no 3 year survivor among patients with four or more tumours. When the number of liver tumours was less than four, the prognosis in patients with unilateral disease was not significantly better than in patients with bilateral disease (P = 0.19). No other liver disease variable seemed to play any role in the prognosis. Extrahepatic disease was associated with a poor prognosis and no 5 year survivor. The length of the tumour-free resection margin was the only treatment variable that varied with the outcome: a resection margin of less than 10 mm was followed by a poor survival. Variables that did not influence survival included uni- or bilateral disease, liver tumour volume, tumour size, type of liver resection, Dukes' classification, differentiation of the primary tumour and synchronous or metachronous disease. It is concluded that resection for liver colorectal secondaries is indicated when there are less than four liver tumours, even if bilateral, no extrahepatic disease is present, and a resection margin of at least 10 mm can be obtained. It should not be performed unless all of these requirements are met.
The pattern Of relapse and factors influencing the site of recurrent disease were studied in 68 patients subjected to liver resection of coloreetal metastases. Fifty-three (78%) patients had recurrence. Liver, lungs, and peritoneal cavity were most frequently involved, and all patients with relapse had recurrence in one or more of these sites. Intraabdominai relapse occurred in 50 (74%) patients (94% of patients with rdapse). The liver was involved in 44 (65%) patients and Was the only site of recurrence in 19 (28%). Extrahepatic metastases developed in 34 (50%) patients. Four or more liver tumors, a resection margin of less than 10 mm, and extrahepatic disease were the main determinants of hepatic recurrence. Bilateral intrahepatic spread, as compared to unilateral disease, major liver resection, as compared to wedge resection, and percent liver tumor volume were also associated with an increased risk of liver recurrence. The presence of extrahepatic disease before resection was the only factor that could be demonstrated to increase the risk of (further) extrahepatic spread. It is concluded that the number of liver metastases, the resection margin, and the presence or absence of extrahepatic disease helps in predicting the risk of hepatic recurrence after resection for colorectai liver cancer. No variable presently available is of any help, however, in predicting the extrahepatic recurrence affecting about half of the patients having no evidence of extrahepatic disease before liver resection. This finding should urge improved evaluation of candidates for liver resection and should influence adjuvant treatment protocols.
We report a case of congenital absence of the portal vein (CAPV) in an adult male who underwent resection for hepatocellular carcinoma. CAPV is a rare anomaly; only 29 cases, mostly in children, have been presented to date. An association between CAPV and cardiac abnormalities, polysplenia syndrome, skeletal abnormalities and liver tumors has been seen in children. To the best of our knowledge this is the first case of CAPV in an adult male resected for hepatocellular carcinoma. However, since CAPV can be without symptoms, the number of undiagnosed cases is not known.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.